The proximity of 5E6 and 3H1 epitopes to the transmembrane domain allows these mAbs to bind to the cell surface that can be exploited for developing MUC16 targeted therapeutics for ovarian cancer. This evidence concerns the gene MUC16 and ovarian cancer.